CCF Comments to Trump Administration Medicaid Drug Rebate Rule

CCF has submitted public comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed Medicaid drug rebate rule which, among other things, would change how drug manufacturers report “best price” under the effective Medicaid Drug Rebate Program. As I have explained, the proposed rule’s best price reporting changes are intended to facilitate […]

New Report Finds Chilling Effect, Avoidance of Health Care Services Among Immigrant Families

As the COVID-19 pandemic continues to wreak havoc across the US, public health experts have emphasized the disparate impact the virus is having on certain groups – those over 65 years old (especially in congregate care settings), those with underlying health conditions, and American Indian/Alaska Native (AI/AN), Black, and Latino communities. Immigrants are also disproportionately […]

Five Steps States Can Take to Address Inequities of Health Crisis

In May, Tekisha Dwan Everette and Karen Siegel from Health Equity Solutions released an article titled, “Five Key Questions State Health Officials Can Ask Right Now to Advance Health Equity During COVID-19 Response Efforts.” Preliminary state COVID-19 data disaggregated by race, geography and gender shows significant disparities in care and infection rates. These disparities are […]

CMS Proposes Medicaid Drug Rebate Changes to Facilitate Commercial Adoption of Value-Based Purchasing Arrangements

On June 19, 2020, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule to change how drug manufacturers would report prices for purposes of the “best price” requirement under the Medicaid Drug Rebate Program (MDRP), among other modifications to the rebate program and to Medicaid coverage of outpatient prescription drugs.  The intent […]